Capital Fund Management (CFM)
NTLA icon

Capital Fund Management (CFM)’s Intellia Therapeutics NTLA Stock Holding History

Capital Fund Management (CFM)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$826K Buy
48,800
+22,700
+87% +$318K ﹤0.01% 1754
2026
Q1 		$335K Buy
+26,100
New +$332K ﹤0.01% 1939
2025
Q4 		– Sell
-35,400
Closed -$611K – 2560
2025
Q3 		$611K Sell
35,400
-48,100
-58% -$592K ﹤0.01% 2257
2025
Q2 		$783K Buy
+83,500
New +$686K ﹤0.01% 2077
2024
Q3 		– Sell
-16,500
Closed -$369K – 2098
2024
Q2 		$369K Sell
16,500
-67,300
-80% -$1.6M ﹤0.01% 1806
2024
Q1 		$2.31M Sell
83,800
-37,400
-31% -$1.04M 0.01% 1376
2023
Q4 		$3.7M Buy
121,200
+80,600
+199% +$2.32M 0.01% 1243
2023
Q3 		$1.28M Buy
+40,600
New +$1.58M ﹤0.01% 1550
2021
Q2 		– Sell
-11,700
Closed -$939K – 1585
2021
Q1 		$939K Buy
+11,700
New +$785K 0.01% 987

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Capital Fund Management (CFM)'s NTLA Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Intellia Therapeutics (NTLA) stake by 59% in Q2 2026, selling an estimated $6.04M and leaving 298,380 shares worth $5.05M. The position accounts for 0.02% of the portfolio, ranked #908.

Capital Fund Management (CFM) first reported a position in NTLA in Q4 2022 and has held it in 10 quarters since. The position peaked at $9.36M in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Capital Fund Management (CFM) held 298,380 shares of Intellia Therapeutics worth $5.05M as of Q2 2026.
  • Capital Fund Management (CFM) sold 431,742 Intellia Therapeutics shares in Q2 2026, an estimated $6.04M.
  • Intellia Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #908 holding.
  • Capital Fund Management (CFM) first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Capital Fund Management (CFM)'s Intellia Therapeutics position peaked at $9.36M in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.